Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology Hematology PA-Chaska — Chaska, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Saint Joseph's Crosslake Clinic — Crosslake, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Coborn Cancer Center at Saint Cloud Hospital — Saint Cloud, Minnesota
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Minnesota: - Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Cambridge Medical Center — Cambridge, Minnesota
- Mercy Hospital — Coon Rapids, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
- Fairview Clinics and Surgery Center Maple Grove — Maple Grove, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Minnesota: - HealthPartners Frauenshuh Cancer Center CRC West — Saint Louis Park, Minnesota
- HealthPartners Cancer Center at Regions Hospital CRC East — Saint Paul, Minnesota
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Minnesota: - Avera Cancer Institute - Marshall ( Site 0122) — Marshall, Minnesota
- M Health Fairview Clinics and Surgery Center ( Site 0019) — Minneapolis, Minnesota
- Metro-Minnesota Community Clinical Oncology ( Site 0014) — Saint Louis Park, Minnesota
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Minnesota: - Minnesota Oncology Hematology PA — Minneapolis, Minnesota
- University of Minnesota Medical Center Fairview — Minneapolis, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Minnesota: - Mayo Clinic- Rochester — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Minnesota: - Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Minnesota: - Research Site 121 — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Federal
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use ola…
Sponsor: VA Office of Research and Development
NCT ID: NCT04038502
Sites in Minnesota: - Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07590934
Sites in Minnesota: - Research Site — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT04868604
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Industry
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.
Sponsor: Syntrix Biosystems, Inc.
NCT ID: NCT06228053
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting Academic/Other
The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assess…
Sponsor: HealthPartners Institute
NCT ID: NCT07354919
Sites in Minnesota: - HealthPartners Frauenshuh Cancer Research Center — Saint Louis Park, Minnesota
- HealthPartners Cancer Center at Regions Hospital — Saint Paul, Minnesota
Phase 1 Recruiting Industry
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered…
Sponsor: Exelixis
NCT ID: NCT05932862
Sites in Minnesota: - Exelixis Clinical Site #14 — Rochester, Minnesota
Phase 1 Recruiting Industry
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Minnesota: - University Of Minnesota — Minneapolis, Minnesota
Phase 1 Recruiting Industry
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Sponsor: Amgen
NCT ID: NCT07140900
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
Phase 1 Recruiting Industry
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter i…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06531499
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Duluth Clinic — Duluth, Minnesota
- St. Luke's Hospital of Duluth — Duluth, Minnesota
- Lake Region Healthcare — Fergus Falls, Minnesota
NA Recruiting Industry
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Sponsor: Axonics, Inc.
NCT ID: NCT06511141
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Minnesota: - Allina Health Cancer Institute — Minneapolis, Minnesota
- Mayo Clinic — Rochester, Minnesota